NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $13.92 -0.02 (-0.14%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RDY alerts:Sign Up Key Stats Today's Range$13.84▼$13.9950-Day Range$12.37▼$14.0052-Week Range$12.26▼$16.89Volume1.25 million shsAverage Volume1.47 million shsMarket Capitalization$11.62 billionP/E Ratio22.17Dividend Yield0.57%Price Target$17.00Consensus RatingModerate Buy Company OverviewDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More… Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 37% of companies evaluated by MarketBeat, and ranked 309th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDr. Reddy's Laboratories has received no research coverage in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth2.50% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 2.50% in the coming year, from $0.80 to $0.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 22.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 22.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.42.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.91% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 12.70%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.76% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.91% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.14 News SentimentDr. Reddy's Laboratories has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Dr. Reddy's Laboratories this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RDY on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Stock News HeadlinesDr. Reddy's Laboratories advances Monday, underperforms competitorsApril 28 at 6:41 AM | marketwatch.comDr. Reddy's Laboratories slides Friday, outperforms competitorsApril 25, 2025 | marketwatch.comSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. You see, I’ve recently uncovered a secret financial plot unfolding in Washington DC…April 30, 2025 | Timothy Sykes (Ad)Dr. Reddy's Laboratories slides Tuesday, underperforms competitorsApril 22, 2025 | marketwatch.comZacks Industry Outlook Dr. Reddy's, Sandoz and Teva PharmaceuticalsApril 16, 2025 | uk.finance.yahoo.comDr. Reddy's Laboratories rises Wednesday, outperforms competitorsApril 16, 2025 | marketwatch.comDr Reddy’s denies reports of cost cut through workforce reductionApril 14, 2025 | seekingalpha.comDr Reddy’s initiates 25% workforce reduction, report suggestsApril 14, 2025 | msn.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $15.79 at the beginning of 2025. Since then, RDY stock has decreased by 11.8% and is now trading at $13.92. View the best growth stocks for 2025 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) posted its quarterly earnings results on Thursday, January, 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 17.87% and a net margin of 17.25%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Shares of Dr. Reddy's Laboratories split on the morning of Tuesday, November 5th 2024. The 5-1 split was announced on Thursday, September 12th 2024. The newly issued shares were issued to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' top institutional investors include Robeco Institutional Asset Management B.V. (1.28%), Bessemer Group Inc. (0.10%), Rhumbline Advisers (0.04%) and Artemis Investment Management LLP (0.03%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings1/23/2025Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees24,800Year Founded1984Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+22.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio22.07 Forward P/E Ratio17.33 P/E GrowthN/ANet Income$668 million Net Margins17.25% Pretax Margin23.22% Return on Equity17.87% Return on Assets12.32% Debt Debt-to-Equity Ratio0.02 Current Ratio1.92 Quick Ratio1.38 Sales & Book Value Annual Sales$311.31 billion Price / Sales0.04 Cash Flow$1.05 per share Price / Cash Flow13.25 Book Value$4.50 per share Price / Book3.08Miscellaneous Outstanding Shares834,772,000Free Float818,045,000Market Cap$11.57 billion OptionableOptionable Beta0.51 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:RDY) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.